GBAF Logo
Global Banking & Finance Awards® 2026 Nominations open, free to enter Nominate now →
H

Hunan Warrant Pharmaceutical Co 688799.SS · CNY

Health Care · Shanghai · 🇨🇳 China

Compare

51.29

+9.13%

Close of 9 Nov 2026, in CNY

Search any instrument

Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.

About Hunan Warrant Pharmaceutical Co

Its shares trade on Shanghai under the ticker 688799.SS. It has been listed since 13 July 2021. In the fiscal year to 31 December 2025, it reported revenue of CN¥1.52bn and net income of CN¥241.5m. At that date it held total assets of CN¥3.05bn and shareholders' equity of CN¥2.04bn.

Hunan Warrant Pharmaceutical Co., Ltd. engages in the production of Chinese medicine. The company is headquartered in Changsha, Hunan. The company went IPO on 2021-07-13. The firm's products include pharmaceutical preparations, raw materials and intermediates, plant extracts and food. Its products cover areas such as digestion, breathing, and anti-infection. The firm mainly conducts business within the domestic market.

Figures and description from our data supplier, not checked against the company's own report.

Company facts

Sector
Health Care
Industry
Pharmaceuticals
Listed since
13 Jul 2021
Employees
1,103

Leadership

Pay as last reported

  • Mr. Bendong HuangChairman of the Board, General Manager, since 2015CN¥1.0m
  • Mr. Yan XuVice Chairman of the Board, Chief Scientific Officer, since 2015CN¥505,400
  • Ms. Guiying WuFinance Director
  • Mr. Xiang GaoDeputy General Manager, Director, since 2015CN¥805,400
  • Mr. Guoxian CaiDeputy General ManagerCN¥802,900
  • Ms. Lin DouDeputy General Manager, since 2024CN¥505,600
  • Mr. Shiqing PiDeputy General ManagerCN¥506,100
  • Mr. Jian XiaoDeputy General Manager
  • Mr. Zhigang ZhouDeputy General Manager
  • Mr. Qiao QiaoSecretary of Board
  • Mr. Jun XieDirector
  • Mr. Cailian KangIndependent DirectorCN¥80,000

Environmental, social and governance

Scores out of 100, from our data supplier

ESG
Overall
0
Environment
0
Social
0
Governance
0

SWOT analysis

AI-generated by our data supplier. Not written or checked by our editors.

AI-generated

Strengths

  • Produces Chinese medicine and pharmaceutical products including preparations, raw materials, and plant extracts.
  • Operates with 1,103 employees and has a domestic market focus.
  • Has a clear product range covering digestion, breathing, and anti-infection areas.

Weaknesses

  • Relies solely on the domestic market for business operations.
  • No international presence or expansion mentioned in the provided information.
  • Limited product diversity beyond pharmaceuticals and food.

Opportunities

  • Potential to expand into international markets for growth.
  • Growing demand for Chinese medicine and pharmaceuticals globally.
  • Opportunity to diversify product offerings beyond current categories.

Threats

  • Dependence on domestic market may limit growth opportunities.
  • Competition within the domestic pharmaceutical sector.
  • No mention of strategies to address potential regulatory changes.

Sources and methodology

Data on this tab
Our data supplier
Chart on the Overview
TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.